Barclays lowered the firm’s price target on Acadia Healthcare (ACHC) to $28 from $35 and keeps an Equal Weight rating on the shares. The firm says that while the in-line Q1 results are a positive step to stabilize the earnings base, it remains cautious given further media and legal risk in April along “with a big step-up in earnings” for the balance of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare: Resilient Performance and Strategic Expansion Justify Buy Rating
- Acadia Healthcare Reports Q1 2025 Results and Growth Plans
- Positive Outlook for Acadia Healthcare: Strong Q1 Performance and Strategic Initiatives Drive Buy Rating
- Acadia Healthcare: Strong Financial Performance and Growth Prospects Amidst Adjusted Price Objective
- Acadia Healthcare price target lowered to $33 from $40 at BofA